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Abstract
Background Application of idarucizumab and hemodialysis are options to reverse the action of the oral anticoagulant dabi-
gatran in emergency situations.
Objectives The objectives of this study were to build and evaluate a mechanistic, whole-body physiologically based pharma-
cokinetic/pharmacodynamic (PBPK/PD) model of idarucizumab, including its effects on dabigatran plasma concentrations 
and blood coagulation, in healthy and renally impaired individuals, and to include the effect of hemodialysis on dabigatran 
exposure.
Methods The idarucizumab model was built with the software packages PK-Sim® and MoBi® and evaluated using the full 
range of available clinical data. The default kidney structure in MoBi® was extended to mechanistically describe the renal 
reabsorption of idarucizumab and to correctly reproduce the reported fractions excreted into urine. To model the PD effects 
of idarucizumab on dabigatran plasma concentrations, and consequently also on blood coagulation, idarucizumab-dabigatran 
binding was implemented and a previously established PBPK model of dabigatran was expanded to a PBPK/PD model. The 
effect of hemodialysis on dabigatran was implemented by the addition of an extracorporeal dialyzer compartment with a 
clearance process governed by dialysate and blood flow rates.
Results The established idarucizumab-dabigatran-hemodialysis PBPK/PD model shows a good descriptive and predictive 
performance. To capture the clinical data of patients with renal impairment, both glomerular filtration and tubular reabsorp-
tion were modeled as functions of the individual creatinine clearance.
Conclusions A comprehensive and mechanistic PBPK/PD model to study dabigatran reversal has been established, which 
includes whole-body PBPK modeling of idarucizumab, the idarucizumab-dabigatran interaction, dabigatran hemodialysis, 
the pharmacodynamic effect of dabigatran on blood coagulation, and the impact of renal function in these different scenarios. 
The model was applied to explore different reversal scenarios for dabigatran therapy.
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article (https ://doi.org/10.1007/s4026 2-019-00857 -y) contains 
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1 Introduction
The prodrug dabigatran etexilate is approved in Europe and 
the USA for the prophylaxis of stroke and embolism and for 
the treatment of deep venous thrombosis [1]. Its active agent 
dabigatran and the main dabigatran metabolite dabigatran-
acyl-glucuronide reversibly bind to and inhibit thrombin and 
thereby delay the blood coagulation. The acyl-glucuronide 
accounts for 10–24% of the total dabigatran plasma concentra-
tion and shows a comparable pharmacodynamic (PD) activity 
[2, 3]. The PD effect of dabigatran is directly correlated to its 
plasma concentration and can be easily assessed with coagu-
lation assays, such as activated partial thromboplastin time 
(aPTT), diluted thrombin time (dTT), ecarin clotting time 
(ECT), or thrombin time (TT) [4]. These coagulation assays 
determine the velocity of blood coagulation and are used to 
quantify the anticoagulant activity of dabigatran [5]. Although 
dabigatran administration does not require routine monitoring, 
these assays, especially dTT and ECT, are important tools to 
determine the dabigatran anticoagulant activity and therefore 
the bleeding risk of patients in emergency situations [6, 7].
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Key Points 
The first whole-body physiologically based pharmacoki-
netic model of idarucizumab has been successfully built 
and evaluated for the prediction of idarucizumab plasma 
concentrations and fractions excreted to urine in healthy, 
elderly, and renally impaired individuals. The impact of 
renal function on the pharmacokinetics of idarucizumab 
was implemented using the reported creatinine clearance 
values of the different study populations to mechanisti-
cally model the extent of passive renal filtration and 
renal reabsorption of idarucizumab.
In a physiologically based pharmacokinetic/pharmaco-
dynamic approach, the validated idarucizumab model 
was extended to describe the idarucizumab-dabigatran 
interaction and to predict the impact of idarucizumab 
on dabigatran plasma concentrations and thus on blood 
coagulation times in healthy individuals, elderly persons, 
renally impaired individuals, and dabigatran-treated 
patients. Furthermore, a dialyzer compartment was 
added, to reproduce and compare the effect of hemodi-
alysis on dabigatran exposure and blood coagulation.
The thoroughly evaluated idarucizumab-dabigatran-
hemodialysis physiologically based pharmacokinetic/
pharmacodynamic model can now be applied to inves-
tigate and predict the outcome of different dabigatran 
reversal regimens and to develop individualized treat-
ment options for patients with reduced renal function.
[11], but idarucizumab as an antibody fragment does not 
contain an Fc region to interact with the Fc receptor. Fur-
thermore, idarucizumab is eliminated via the kidneys, as 
it is small enough for glomerular filtration [12], which is 
followed by active uptake into proximal tubule cells by the 
multi-ligand receptors megalin and cubilin. After binding 
to megalin or cubilin on the cellular surface, these receptors 
mediate the endocytosis of idarucizumab into tubular cells, 
where it undergoes lysosomal degradation into amino acids, 
which are returned to the circulation [13]. Consequently, 
idarucizumab is eliminated rapidly from the body, showing 
a short initial half-life of 45 min [10]. Following its intrave-
nous administration, idarucizumab strongly binds to dabi-
gatran and its glucuronide in the blood, causing a shift in the 
dabigatran plasma-tissue ratio that leads to a redistribution 
of dabigatran from the extravascular space into the plasma. 
Therefore, a sufficient amount of idarucizumab has to be 
applied to intercept this redistributing dabigatran, as other-
wise the rebounding dabigatran plasma concentrations cause 
a second increase of its anticoagulant effects.
As idarucizumab [14] as well as dabigatran [15] are 
largely eliminated via renal metabolism or excretion, altered 
renal function as a result of increasing age or renal impair-
ment impacts the pharmacokinetics of both drugs, which can 
also influence their interaction. Prediction of the outcome of 
dabigatran reversal gains further complexity from the high 
inter-individual variability of dabigatran plasma concentra-
tions, caused not only by differences in renal function but 
also by the impact of P-glycoprotein (Pgp) on the absorption 
of dabigatran etexilate after oral administration [16]. Physi-
ologically based pharmacokinetic (PBPK) modeling can be 
a helpful tool to generate further insights into the complex 
underlying mechanisms that determine the pharmacokinet-
ics of idarucizumab, dabigatran, and their interactions and 
to guide dose recommendations.
The aims of this analysis were (1) to establish a whole-
body PBPK model of idarucizumab, (2) to describe and 
predict the interaction of idarucizumab with dabigatran in 
healthy and renally impaired individuals, (3) to establish a 
hemodialysis model for dabigatran, (4) to predict the effects 
of idarucizumab and hemodialysis on the pharmacodynam-
ics of dabigatran by establishing a PBPK/PD model of dabi-




PBPK modeling was performed with the software pack-
ages PK-Sim® and MoBi®, using the PBPK platform for 
whole-body PBPK modeling of large molecules (version 8.0, 
In the case of emergency surgeries or life-threatening 
bleeding events, patients receiving dabigatran treatment 
need removal of dabigatran and reversal of its anticoagulant 
effects. As dabigatran shows low plasma protein binding 
(35%) [8] and a moderate volume of distribution (60–70 
L) [9], it can be extracted by hemodialysis. Four hours of 
hemodialysis remove approximately 50–60% of dabigatran 
from plasma [9]. For a more immediate, complete, and 
convenient reversal, the humanized monoclonal antibody 
fragment idarucizumab was developed and approved as a 
specific antidote.
Idarucizumab binds dabigatran and dabigatran-acyl-glu-
curonide with very high specificity and affinity (Kd = 2.1 
pmol/L) [10]. The pharmacokinetics of idarucizumab are 
governed by its molecular weight (MW = 47.8 kDa), which 
limits passive distribution into tissues. The main clearance 
processes are endocytosis as well as renal metabolism and 
excretion [11]. Endocytosis is followed by lysosomal deg-
radation throughout the body. The neonatal Fc receptor can 
rescue whole antibodies from lysosomal degradation by 
binding to their Fc region and returning them to circulation 
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part of the Open Systems Pharmacology Suite, www.open-
syste ms-pharm acolo gy.org). Parameter optimization using 
the Monte Carlo algorithm and a sensitivity analysis were 
performed within MoBi®. Digitization of published plasma 
concentration–time and effect–time profiles of dabigatran 
and idarucizumab was accomplished using GetData Graph 
Digitizer (version 2.26.0.20, © S. Fedorov). Pharmacoki-
netic parameter analysis and plots were created with MAT-
LAB® R2019a (The MathWorks, Inc., Natick, MA, USA).
2.2  Idarucizumab Physiologically Based 
Pharmacokinetic Model
An extensive literature research was performed to gain 
information on the physicochemical properties as well as 
the absorption, distribution, metabolism, and excretion pro-
cesses of idarucizumab and to obtain parameters describ-
ing its interaction with dabigatran. Furthermore, published 
clinical studies were collected to provide concentration–time 
profiles and fraction excreted to urine data of idarucizumab 
and dabigatran as well as effect–time profiles of dabigatran. 
Digitized observed data from these clinical studies were 
assigned to the training dataset, used for model development, 
or to the test dataset, used for model evaluation. Parameters 
that could not be informed from the literature were opti-
mized by fitting the model to the entire training dataset. 
Details on all utilized clinical studies and on their assign-
ment to a test or training dataset are provided in Table 1 and 
Table S1 of the Electronic Supplementary Material (ESM).
For the presented PBPK analysis, experimental data of 
five published clinical trials were available [14, 17–23], 
including healthy, elderly, and renally impaired Caucasian 
individuals, healthy Japanese individuals, and a diverse 
group of patients requiring dabigatran reversal. Idaruci-
zumab was applied intravenously in doses between 20 mg 
and 8000 mg, either alone or in combination with orally 
applied, steady-state dabigatran (150 mg or 220 mg of dabi-
gatran etexilate). In total, 38 plasma concentration–time and 
24 fraction excreted to urine profiles of idarucizumab were 
available for the idarucizumab PBPK model. Furthermore, 
the studies provide 15 plasma concentration–time profiles 
of dabigatran  with corresponding effect–time profiles for 
aPTT, dTT, ECT, and TT. Three additional reports were 
found for the development of the dabigatran hemodialysis 
model, providing four plasma concentration–time profiles of 
dabigatran during dialysis [9, 24, 25].
Reported values for age, weight, height, and sex were 
used to simulate the different clinical studies. Renal func-
tion was modeled using reported values for creatinine clear-
ance (CrCl). It was assumed that the reported CrCl equals 
the glomerular filtration rate (GFR), and individual values 
for the parameter “specific glomerular filtration rate” were 
calculated and implemented, normalizing the reported CrCl 
values to the kidney weights of the respective PK-Sim® 
individuals. In cases where CrCl was not reported, the 
model used the specific glomerular filtration rate calculated 
by PK-Sim® based on the individual subject characteristics. 
Physiological differences associated with aging and Japanese 
ethnicity were taken into account as predefined in the PBPK 
modeling platform.
2.2.1  Renal Handling of Idarucizumab
To describe the tubular reabsorption and degradation of 
idarucizumab, the kidney compartment provided within the 
modeling platform was extended by addition of a proximal 
tubule compartment in MoBi®, according to a previously 
developed PBPK model by Balazki et al. [26]. The new 
model structure describes glomerular filtration of idaruci-
zumab from the blood into the new tubule compartment and 
subsequent flow from the tubule into the urine, as further 
outlined in the ESM.
For the implementation of megalin-mediated endocytosis 
and degradation of idarucizumab in the tubule, an endo-
somal compartment was added into the intracellular sub-
compartment of the kidney. This endosomal compartment 
was scaled according to the approach used in the PK-Sim® 
protein model, which is further outlined in the ESM. To 
simplify the renal uptake described in Sect. 1, megalin was 
implemented as a transporter, mediating the transport of 
idarucizumab from the tubule lumen directly into the endo-
somal compartment, as illustrated in Fig. 1c. The transport 
was described using Michaelis-Menten kinetics:
where v0 is the reaction rate, kcat is the catalytic rate constant 
that describes the turnover per time, [E] is the transporter 
concentration, [I] is the idarucizumab concentration, and Km 
is the substrate concentration that is needed to reach half of 
kcat [E] = Vmax. Lysosomal degradation of idarucizumab was 
introduced into the kidney endosome compartment with the 
default equation used in PK-Sim®, as described in the ESM.
2.3  Idarucizumab‑Dabigatran Interaction
A recently published PBPK model of dabigatran, its prod-
rug dabigatran etexilate, and its metabolite dabigatran-acyl-
glucuronide [27] was merged with the final idarucizumab 
model. As it is described that idarucizumab is able to bind 
dabigatran as well as its glucuronide in a 1:1 stoichiometric 
ratio [28], both interactions were implemented accordingly 
(see the ESM).
The formed idarucizumab-dabigatran and idarucizumab-
dabigatran glucuronide complexes were described with the 
(1)v0 =
kcat ⋅ [E] ⋅ [I]
Km + [I]
,
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same physicochemical and absorption, distribution, metabo-
lism, and excretion properties as idarucizumab, except for 
the molecular weights, which have been adjusted. Tubular 
reabsorption and degradation of the complexes were enabled 
(see ESM).
In idarucizumab-dabigatran interaction studies, the idaru-
cizumab quantification assay did not differentiate between 
free idarucizumab and the idarucizumab-dabigatran com-
plexes. Because idarucizumab and the complexes are repre-
sented as different molecules in the model, the idarucizumab 
plasma concentration determined in the clinical studies was 
described in the model as “sum idarucizumab”, by adding 
up the predicted concentrations of idarucizumab and the 
idarucizumab-dabigatran complexes.
The dabigatran quantification assay determined the con-
centration of pharmacologically active dabigatran, which 
consists of the plasma concentrations of dabigatran and 
its acyl-glucuronide that are neither bound to plasma pro-
teins nor captured by idarucizumab [14]. Therefore, this 
measured plasma concentration was described in the model 
as “unbound sum dabigatran”, by adding up the predicted 
concentrations of unbound dabigatran and unbound dabi-
gatran-glucuronide. A detailed description of dabigatran 
and idarucizumab plasma and urine measurements and their 
implementation in the model is provided in Sect. S1.1 of 
the ESM.
2.4  Hemodialysis Model
For hemodialysis modeling, the spatial structure of the 
human organism within the PBPK modeling platform was 
extended by a dialyzer compartment in  MoBi®, connected 
to the arterial and venous blood compartments. The filtra-
tion of dabigatran and dabigatran glucuronide from venous 
blood into the dialyzer is described by Eq. (2), adapted from 
a pharmacometric analysis of dabigatran hemodialysis by 
Liesenfeld et al. [29]:
Fig. 1  Final model structure. a The model consists of 17 organ com-
partments, connected by arterial and venous blood flow (red/blue 
arrows) and lymph flow (dashed arrows). b Each organ is sub-divided 
into plasma (also containing red blood cells), endothelial space, inter-
stitial space, and intracellular space. Dabigatran (orange) as a small 
molecule can distribute freely into all subcompartments, while dis-
tribution of the protein idarucizumab (blue) is restricted to plasma 
and the interstitial space, with the latter accessible via pores in the 
endothelial cell layer. Therefore, interaction of idarucizumab and 
dabigatran mainly occurs in plasma and to a lower extent in the inter-
stitial space. Furthermore, idarucizumab enters endothelial cells via 
endocytosis, where it undergoes lysosomal degradation. c The kidney 
structure was extended by a tubule compartment and an endosome 
compartment. Idarucizumab and idarucizumab-dabigatran complexes, 
filtered from blood into the tubule, are actively transported into the 
endosome by megalin (black), where they undergo lysosomal degra-
dation. During lysosomal breakdown of the complexes, dabigatran is 
released and shuttled back into the tubule via exocytosis and excreted 
with the urine. d An extracorporeal compartment, representing a dial-
ysis machine, was implemented and connected to the venous blood 
flow. A clearance process describes the filtration of dabigatran from 
venous blood into the dialyzer compartment
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where  CLDialysis is the dialysis clearance, BFR is the blood 
flow rate, DFR is the dialysate flow rate, and KoA is the 
mass transfer area coefficient for dabigatran, depending 
on the dialysis filter that is used. KoA was adopted from 
Liesenfeld et al. [29], while BFR and DFR were taken from 
the respective publications, shown in Table S1 of the ESM.
2.5  Dabigatran Pharmacodynamics
The aPTT, dTT, ECT, and TT assays are performed to deter-
mine the PD anticoagulant activity of dabigatran. Because 
the outcome of these assays depends on the dabigatran 
plasma concentrations, a concentration–effect relationship 
of dabigatran and each marker was implemented, to extend 
the PBPK model to a PBPK/PD model.
Data of the respective coagulation assays were fit-
ted using linear and combined linear and Emax models, to 
describe their correlation with the dabigatran plasma con-
centrations, similar to the approach of Liesenfeld et al. [30]. 
The simplest equation to accurately describe the observed 
concentration–effect relationship for each marker was then 
incorporated in the PBPK/PD model.
2.6  Physiologically Based Pharmacokinetic Model 
Evaluation
Predicted plasma concentration–time profiles of idaruci-
zumab and dabigatran and effect–time profiles of dabigatran 
were compared to the data observed in the clinical studies of 
the test dataset and further evaluated in goodness-of-fit plots. 
The performance of the final idarucizumab PBPK model 
was additionally evaluated by comparison of predicted to 
observed area under the plasma concentration–time curve 
(AUC) values. Model prediction was deemed successful 
when the PK parameters lay within the two-fold acceptance 
range.
As quantitative measures of the descriptive and predictive 
performance of the models, mean relative deviation (MRD) 
of all predicted plasma concentrations and geometric mean 
fold error (GMFE) of all predicted AUCs were calculated. 
Calculation of MRD and GMFE is described in the ESM.
2.7  Prediction of Dabigatran Reversal Scenarios
After the evaluation of the PBPK models, various reversal 
scenarios of idarucizumab administration and hemodialysis 
for dabigatran reversal were predicted. A male Caucasian 




























GFR of 62 mL/min was created for these predictions, based 
on preliminary results of the RE-VERSE AD study, reported 
by Pollack et al. [31]. Administration of 220 mg of dabi-
gatran etexilate twice a day was chosen for all predictions.
3  Results
3.1  Idarucizumab Physiologically Based 
Pharmacokinetic Model
The final idarucizumab PBPK model precisely describes 
and predicts the plasma concentration–time profiles over 
the entire dosing range reported in the literature, and it fur-
thermore reliably predicts its pharmacokinetics in elderly 
and renally impaired Caucasian individuals as well as in 
healthy Japanese individuals. The compartmental structure 
of the model as well as of the kidney extension are presented 
in Fig. 1. The final model applies lysosomal degradation of 
idarucizumab in endothelial cells throughout the body as 
well as glomerular filtration with subsequent tubular reab-
sorption via megalin followed by endosomal degradation. 
Dose-dependent urinary excretion of idarucizumab was 
observed in vivo and implemented into the model via the 
Michaelis-Menten kinetics of megalin.
For the description of idarucizumab pharmacokinetics 
in elderly and renally impaired individuals, changes in kid-
ney function were implemented based on the reported CrCl 
values, as described in Sect. 2.2. This resulted in a good 
description of the idarucizumab plasma concentrations in 
these individuals, with an under-prediction of the urinary 
excretion. Adjusting the active uptake of idarucizumab into 
renal tubule cells of the renally impaired patients, a correla-
tion between the megalin  kcat and the reported CrCl could be 
demonstrated (Fig. S1 and Table S2 of the ESM), and was 
incorporated into the model using an Emax function (Equa-
tion S9 of the ESM), decreasing megalin kcat with decreasing 
CrCl.
When trying to describe the pharmacokinetics of idaruci-
zumab in Japanese individuals, plasma concentrations were 
under-predicted. By reducing the parameter “GFR fraction” 
from 0.32 to 0.26 (both values are optimized, as idaruci-
zumab is not freely filtered, owing to its size of 47.8 kDa) 
to model the Japanese population, the model performance 
could be significantly improved, which is reflected by a 
decrease of the mean MRD by 9%. Predicted vs observed 
plasma concentration–time profiles using both GFR frac-
tions are presented in Figs. S5 and S6 of the ESM with cor-
responding MRD values shown in Table S4 of the ESM. 
The parameters used in the final model are summarized in 
Table 2.
The good model performance is demonstrated by com-
parison of predicted to observed plasma concentration–time 
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profiles and fraction excreted to urine data in Fig. 2 and Figs. 
S2–S4 of the ESM. Goodness-of-fit plots and predicted com-
pared to observed AUC values are presented in Fig. 3. Mean 
predicted plasma concentration MRD and AUC GMFE val-
ues (and ranges) are 1.24 (1.08–1.56) and 1.14 (1.00–1.54), 
respectively, with MRD (Table S5 of the ESM) and GMFE 
(Table S6 of the ESM) values for all individual studies below 
the prediction acceptance limit of 2, further illustrating the 
good model performance. A sensitivity analysis showed that 
the model predictions are sensitive to the value of the GFR 
fraction and the individual GFR (Fig. S7 of the ESM).
3.2  Idarucizumab‑Dabigatran Interaction
The model describing the interaction of idarucizumab and 
dabigatran was established for all populations outlined in 
Sect. 2.2. The interaction parameters are included in the 
model parameter table (Table 2).
The final idarucizumab-dabigatran model includes bind-
ing of idarucizumab to dabigatran and to dabigatran glu-
curonide in plasma and the interstitial space. Furthermore, 
the model applies lysosomal degradation of the resulting 
complexes in endothelial cells throughout the body, as well 
as glomerular filtration with subsequent uptake by megalin 
and degradation in the renal tubules. The idarucizumab-
bound dabigatran is not degraded in the kidney endosome, 
but released during the breakdown of idarucizumab and 
returned to the tubule, where it is excreted with the urine. 
These processes are illustrated in Fig. 1c and in the ESM.
To account for the highly variable bioavailability of 
oral dabigatran, simulated dabigatran etexilate doses were 
adjusted to match the observed data before idarucizumab 
co-administration. The absolute bioavailability of dabigatran 
following oral administration of dabigatran etexilate is 3–7% 
[1]. Dabigatran etexilate, but not dabigatran, is a substrate of 
Pgp and the absolute bioavailability of orally administered 
dabigatran is susceptible to inhibition of Pgp and variabil-
ity in Pgp expression [32]. The adjusted dabigatran etex-
ilate doses vary between 76% (220 mg → 166.11 mg) and 
107% (150 mg → 160.13 mg) of the actually applied doses. 
This dose adjustment of less than 25% lies well within the 
reported inter-individual variability of dabigatran [33].
Plots of predicted compared to observed plasma and urine 
concentration–time profiles of all idarucizumab-dabigatran 
interaction studies obtained from the literature are shown in 
semi-logarithmic plots in Fig. 4 and Figs. S8 and S9 of the 
ESM, illustrating the good prediction of the drastic reduc-
tion of dabigatran plasma concentrations by idarucizumab. 
Table 2  Drug-dependent parameters of the final idarucizumab physiologically based pharmacokinetic model
DAB dabigatran, DABG dabigatran glucuronide, FcRn neonatal Fc receptor, GFR glomerular filtration rate, GFRIND GFR of the simulated indi-
vidual
a Calculated in PK-Sim®
b Idarucizumab has no Fc-region to interact with FcRn
c kcat calculated individually for each simulation as a function of  GFRIND
d Values for Caucasian and Japanese individuals, respectively
Parameter Unit Value used in simulation Literature value References Description
Idarucizumab model
 MW kDa 47.8 47.8 [20] Molecular weight
 fu, plasma % 100 100 [20] Fraction unbound
 Radius (solute) nm 3.23 3.19a – Solute radius
 Kd (FcRn) µmol/L No  bindingb – – Dissociation constant
 Km (megalin) µmol/L 0.20 – – Michaelis-Menten constant
 kcat (megalin) 1/min (kcat,max*GFRINDn)/
(GFR50n+ GFRINDn)c
– – Catalytic rate constant
 GFR fraction – 0.32/0.26d – – Fraction of GFR used for passive elimina-
tion by the kidney
 GFR50 mL/min 73.31 – – GFR needed to reach half of megalin kcat, max
 kcat,max 1/min 0.05 – – Maximal catalytic rate constant value
 n – 1.64 – – Hill factor
Idarucizumab-DAB interaction model
 Kd (DAB) pmol/L 2.1 2.1 [37] Dissociation constant
 koff (DAB) 1/s 7 × 10−6 3 × 10−6, 7 × 10−6 [10, 37] Dissociation rate constant
 Kd (DABG) pmol/L 2.1 – Dissociation constant
 koff (DABG) 1/s 7 × 10−6 – Dissociation rate constant
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Fig. 2  Idarucizumab (IDA) 
plasma concentrations (dark 
blue) and fractions excreted to 
urine (fe to urine) (light blue) 
following administration of 
different doses (1000, 4000, or 
5000 mg) as bolus injections 
to a, b healthy Caucasian indi-
viduals [18, 20]; c, d Caucasian 
individuals between 65 and 80 
years of age, pre-treated with 
220 mg of dabigatran etexilate 
(DE) twice a day (bid) [14, 17]; 
e, f Caucasian individuals with 
mild renal impairment (RI), 
pre-treated with 150 mg of DE 
bid [14, 17], and g, h healthy 
Japanese individuals [19, 21]. 
Clinically observed data are 
shown as dots; solid lines indi-
cate predicted plasma concen-
trations, dashed lines indicate 
predicted fe to urine
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Goodness-of-fit plots of dabigatran plasma concentrations 
and fractions excreted to urine following idarucizumab 
administration are presented in Fig. 3d and e. 83% of the pre-
dicted plasma concentrations lie within the two-fold range of 
the observed values with a mean MRD of 2.14 (1.38–5.10).
3.3  Hemodialysis Model
To explore the efficiency of hemodialysis for dabigatran 
reversal, an extension of the dabigatran model was developed 
by adding a dialyzer compartment and adapting the hemodi-
alysis clearance model established by Liesenfeld et al. [29] 
for dabigatran and dabigatran glucuronide as described in 
Sect. 2.4. Concentration–time profiles taken from clinical 
studies are summarized in Table S1 of the ESM, and pre-
dicted compared to observed plasma profiles are shown in 
Fig. 5. This semi-mechanistic approach successfully predicts 
the reduction of the sum dabigatran plasma concentrations in 
different hemodialysis settings, such as different hemodialy-
sis times, blood flow rates, and dialysate flow rates. During 
hemodialysis sessions of 3, 4, and 6 h, plasma concentration 
reductions by 41%, 49%, and 65% have been reported, while 
the presented model predicts reductions by 36%, 46%, and 
56%, respectively.
3.4  Dabigatran Pharmacodynamics
To describe the PD effects of dabigatran, a PBPK/PD model 
was established, linking the unbound sum dabigatran plasma 
concentrations to the different coagulation assay results. Fol-
lowing the analysis of experimental data, a combined linear 
and Emax model was selected to model the correlation of 
unbound sum dabigatran plasma concentrations to aPTT and 
TT coagulation times, while a linear model was sufficient 
to describe the effect of unbound sum dabigatran on dTT 
and ECT coagulation times. Similar approaches have been 
described by Liesenfeld et al. [30] and Stangier et al. [3, 6].
The resulting concentration–effect functions are shown in 
Fig. 6 (left column), with the corresponding equations docu-
mented in the ESM. Representative predicted effect–time 
profiles compared to the respective observed data and good-
ness-of-fit plots of all predicted compared to observed effect 
data are also presented in Fig. 6 and demonstrate the good 
performance of the PBPK/PD model. For aPTT, dTT, ECT, 
Fig. 3  Predicted (pred) compared to observed (obs) a, d plasma con-
centrations; b, e fractions excreted to urine (fe to urine), and c areas 
under the plasma concentration–time curves (AUC), of idarucizumab 
(IDA) (upper row) and dabigatran (DAB) (lower row). The line 
of identity is shown as a solid line; the 0.8- to 1.25-fold bioequiva-
lence limits are shown as dotted lines; the 0.5- to 2.0-fold prediction 
acceptance limits are shown as dashed lines. conc concentration, DE 
dabigatran etexilate
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Fig. 4  Plasma concentrations (upper rows) and fractions excreted to 
urine (fe to urine) (lower rows) of dabigatran (DAB) (orange) and 
idarucizumab (IDA) (blue) during dabigatran etexilate (DE) treatment 
(220 mg twice a day (bid), for 3.5 days), followed by administration 
of different doses of IDA for DAB reversal (1000–7500 mg, at 74 h, 
arrow) in a–c: healthy Caucasian individuals [18, 23] and d–f renally 
impaired Caucasian individuals [14, 17]. Clinically observed data are 
shown as dots; solid lines and dashed lines indicate the model pre-
diction. mod moderate, RI renal impairment, unb sum unbound sum, 
unconj unconjugated
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and TT, 98%, 99%, 98%, and 97% of the predicted values 
are within the two-fold range of the observed data, resulting 
in mean MRD values of 1.16, 1.11, 1.16, and 1.27, respec-
tively. Goodness-of-fit plots as well as MRD calculations 
include PD measurements before and after the administra-
tion of idarucizumab. Mean relative deviation values of all 
clinical studies are shown in Table S8 of the ESM. Further 
plots, showing the predictions of all available idarucizumab-
dabigatran studies that include coagulation measurements, 
are presented in Figs. S11–S14 of the ESM.
3.5  Prediction of Dabigatran Reversal Scenarios
The final models were used to predict different dabigatran 
reversal scenarios. The results of those predictions are 
shown in Fig. 7. The recommended dosing regimen of idaru-
cizumab was compared to a standard hemodialysis protocol, 
regarding their effects on dabigatran plasma concentrations 
and diluted thrombin time (Fig. 7a, b). Furthermore, admin-
istrations of idarucizumab as a bolus or a 2-h infusion were 
compared (Fig. 7c), to evaluate if longer infusion times 
could reduce the dabigatran rebound. In addition, combined 
treatments of idarucizumab and hemodialysis were predicted 
(Fig. 7d), to assess if hemodialysis could support idaruci-
zumab treatment and reduce dabigatran rebound, and if 2500 
mg of idarucizumab combined with hemodialysis could be 
as effective as the standard idarucizumab dosing regimen 
of 2 × 2500 mg.
The predictions show that administration of the standard 
dosing regimen of 2 × 2500 mg results in complete dabi-
gatran reversal, while 4 h of hemodialysis reduce the dabi-
gatran plasma concentration by approximately 60%. Further-
more, the administration of 1 × 2500 mg idarucizumab as a 
2-h infusion markedly reduces the rebound effect compared 
with the administration of 1 × 2500 mg as a bolus injection. 
Fig. 5  Plasma concentrations of 
sum dabigatran (DAB) before, 
during, and after hemodialysis. 
Start of hemodialysis is indi-
cated by arrows. a Dabigatran 
etexilate (DE) is administered 
three times in doses of 150 
mg, 110 mg, and 75 mg. Blood 
flow rate (BFR) = 200 mL/min 
during two 4-h hemodialysis 
sessions. b DE is administered 
four times in doses of 150 mg 
bid. BFR = 320 mL/min during 
a 6-h hemodialysis. c DE is 
administered six times in doses 
of 150 mg bid. BFR = 375 mL/
min during a 3-h hemodialysis. 
d DE is administered three 
times in doses of 150 mg, 110 
mg, and 75 mg. BFR = 400 mL/
min during two 4-h hemodialy-
sis sessions. Clinically observed 
data are shown as dots; solid 
lines indicate the model predic-
tion
Fig. 6  Coagulation times as functions of unbound sum dabigatran 
(unb sum DAB) plasma concentrations (left column), in representa-
tive effect–time plots (middle) during dabigatran etexilate (DE) treat-
ment (220 mg twice a day (bid), for 3.5 days) followed by adminis-
tration of 1000 mg of idarucizumab (IDA) for dabigatran reversal 
(at 242 h, arrow) in healthy Japanese individuals [19, 21] and physi-
ologically based pharmacokinetic/pharmacodynamic (PBPK/PD) 
model performance in goodness-of-fit plots (right column). Clini-
cally observed data are shown as dots; colored solid lines indicate 
the model predicted coagulation times. The line of identity is shown 
as a black solid line; the 0.8- to 1.25-fold bioequivalence limits are 
shown as black dotted lines; the 0.5- to 2.0-fold prediction acceptance 
limits are shown as dashed lines. aPTT activated partial thromboplas-
tin time, dTT diluted thrombin time, ECT ecarin clotting time, JPN 
Japanese, obs observed, PD pharmacodynamics, pred predicted, TT 
thrombin time
◂
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Fig. 7  Predicted dabigatran 
plasma concentrations (left 
column) and diluted thrombin 
times (dTT) (right column) for 
different reversal scenarios. 
Dabigatran etexilate (DE) is 
administered in doses of 220 mg 
twice a day (bid). a Standard 
idarucizumab (IDA) dosing 
regimen of two bolus injections 
of 2500 mg. b 4-h hemodialysis 
with a blood flow rate (BFR) 
of 400 mL/min and a dialysate 
flow rate (DFR) of 700 mL/
min. c Comparison of different 
IDA administration protocols: 
application of 2500 mg as a 
bolus injection (solid lines) vs 
application as a 2-h infusion 
(dashed lines). d 2-h infusions 
of 2500 mg (dashed lines) or 
3500 mg (dotted lines) of IDA, 
applied in combination with 
a 6-h hemodialysis. The grey 
dotted line shows the threshold 
for complete dabigatran reversal 
of 20 ng/mL. unb sum DAB 
unbound sum dabigatran
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When hemodialysis is started after the 2-h infusion of 1 × 
2500 mg (Fig. 7d), the rebound is further reduced and close 
to the threshold for complete reversal (20 ng/mL) [14]. To 
achieve complete reversal with a combined treatment of a 
single dose of idarucizumab and hemodialysis, the idaruci-
zumab dose has to be elevated to 3500 mg.
4  Discussion
The presented idarucizumab PBPK model accurately 
describes and predicts plasma concentration–time profiles 
and fractions excreted to urine over the full range of doses 
and administration protocols reported in the literature. The 
model has been qualified to describe the PK and PD inter-
actions of the large molecule idarucizumab with the small 
molecule dabigatran within the same PBPK modeling envi-
ronment, and has been applied to explore dabigatran reversal 
with idarucizumab or hemodialysis in a PBPK/PD approach.
For a mechanistic description of the renal handling of 
idarucizumab, the kidney structure was extended by a tubule 
compartment with megalin-mediated transport from the 
tubule lumen into the renal intracellular endosome. This is 
to our knowledge the first PBPK modeling approach that 
includes megalin-mediated endocytosis into proximal tubu-
lar cells as a process involved in the renal handling of thera-
peutic proteins. In animals, it was demonstrated that renal 
dysfunction can lead to reduced expression of megalin via 
the release of inflammatory mediators [34–36]. In the pre-
sented analysis, a correlation between CrCl and the idaruci-
zumab reabsorption via megalin was observed, decreasing 
the megalin activity with decreasing renal function. This cor-
relation was implemented, to correctly describe the urinary 
excretion of idarucizumab in patients with different stages 
of renal impairment. Using the age-dependent physiological 
parameters in the PK-Sim® database and the reported actual 
CrCl to generate the individuals for the different studies, no 
further adjustment of the model was necessary to describe 
the pharmacokinetics of idarucizumab in renally impaired 
patients. Physiological characteristics of Japanese individu-
als, also provided in the modeling platform, were used to 
describe the pharmacokinetics of idarucizumab in Japanese 
populations. Yet, the idarucizumab plasma concentrations 
in Japanese volunteers were under-predicted throughout all 
simulated profiles, which could be significantly improved 
by reducing the parameter “GFR fraction” from 0.32 to 0.26 
(both values are optimized) for the Japanese population. No 
explanation for these observed ethnic differences could be 
found in the literature.
Before establishing the interaction of idarucizumab and 
dabigatran, a previously published dabigatran PBPK model 
[27] was evaluated by predicting dabigatran plasma con-
centrations without co-administration of idarucizumab. The 
excellent model performance is summarized in goodness-of-
fit plots presented in Fig. S10 of the ESM and MRD values 
are shown in Table S7 of the ESM.
The parameters to model the idarucizumab-dabigatran 
interaction were taken from the literature without any fur-
ther adjustment. With this parameterization, the model suc-
cessfully describes the drastic and complete reduction of 
dabigatran concentrations in the plasma of healthy subjects 
and patients, observed after idarucizumab application.
As it has been postulated that the pharmacokinetics of 
the idarucizumab complexes do not differ from those of 
idarucizumab alone [10], endosomal uptake and degrada-
tion of these complexes in the kidney were included into the 
model. During the breakdown of the complexes, dabigatran 
is released and the free dabigatran escapes endosomal deg-
radation and is excreted with the urine [10]. So far, there is 
no information on the lysosomal handling of the small mol-
ecule dabigatran and how it is released back into the tubule. 
Therefore, a simple exocytotic transport of dabigatran from 
the endosome to the tubule was implemented to describe the 
observed dabigatran fraction excreted to urine. Dabigatran 
was not transported back into the systemic circulation in our 
model as this would result in a second plasma rebound, not 
matching the observed data.
The final idarucizumab-dabigatran PBPK/PD model 
adequately predicts the impact of dabigatran on aPTT, dTT, 
ECT, and TT as well as the effect of dabigatran reversal by 
idarucizumab on these coagulation markers. After successful 
evaluation, this model was used to predict different dabi-
gatran reversal scenarios for a typical patient. Based on the 
population of the idarucizumab phase III study “RE-VERSE 
AD”, the average patient in need of idarucizumab shows a 
CrCl of 62 mL/min. As the GFR has a significant impact on 
the pharmacokinetics of idarucizumab and dabigatran, it is 
important to consider the renal function during the modeling 
of idarucizumab and idarucizumab-dabigatran studies. Our 
predictions show that the standard idarucizumab dosing reg-
imen of two 2500-mg bolus injections results in a complete 
and immediate reduction in dabigatran plasma concentra-
tions, whereas a 4-h hemodialysis reduces dabigatran plasma 
concentrations by approximately 60%. These findings are 
in accordance with current treatment recommendations, 
confirming the recommended idarucizumab regimen of 2 
× 2500 mg. Compared to hemodialysis, administration of 
idarucizumab ensures immediate and complete dabigatran 
reversal and is therefore a safer and more convenient, but 
also more expensive therapy. Our results further suggest 
that longer idarucizumab infusion times have the potential 
to reduce dabigatran rebound and that a combination with 
hemodialysis could further suppress the rebound. This might 
be helpful for patients with moderate or severe renal impair-
ment, where a stronger dabigatran rebound is expected, 
or in situations when there is not enough idarucizumab 
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available and lower doses have to be administered. Addi-
tional clinical data are needed to corroborate this hypothesis.
5  Conclusions
A comprehensive and mechanistic PBPK/PD model to study 
dabigatran reversal has been established, which includes 
whole-body PBPK modeling of idarucizumab, the idaruci-
zumab-dabigatran interaction, dabigatran hemodialysis, the 
dabigatran plasma concentration–effect relationship, and the 
impact of renal impairment in these different scenarios. The 
presented idarucizumab PBPK model is the first published 
in the literature and the idarucizumab-dabigatran interac-
tion model successfully predicts the changes in dabigatran 
plasma concentrations and the PD effects on coagulation 
times. Model building and evaluation of this PBPK/PD 
model are transparently documented, including the model 
performance for all clinical studies obtained from the lit-
erature. The presented model will be freely available in the 
Open Systems Pharmacology repository (https ://www.open-
syste ms-pharm acolo gy.org) and can be applied to investigate 
and understand the pharmacokinetics and pharmacodynam-
ics of idarucizumab and dabigatran as well as the outcomes 
of different dosing regimens. Furthermore, the thorough 
analysis and implementation of the impact of renal function 
on all aspects of this PBPK/PD model make it applicable as 
a tool to guide individual idarucizumab dosing in clinical 
practice, taking us one step closer to our ultimate goal of 
precision medicine.
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